Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis
Multiple sclerosis is an autoimmune neurodegenerative disease and one of the most significant challenges in modern neurology, impacting approximately 2.8 million people globally. As a multifactorial condition, susceptibility to MS can result from a combination of genetic and environmental factors. C...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-08-01
|
| Series: | Non-coding RNA Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468054025000575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839603990739812352 |
|---|---|
| author | Bruna De Felice Elisabetta Signoriello Concetta Montanino Giuseppe Romano Deborah Archetto Elisabetta Maida Martina Marciano Simona Bonavita Giacomo Lus Federica Farinella Cinzia Coppola |
| author_facet | Bruna De Felice Elisabetta Signoriello Concetta Montanino Giuseppe Romano Deborah Archetto Elisabetta Maida Martina Marciano Simona Bonavita Giacomo Lus Federica Farinella Cinzia Coppola |
| author_sort | Bruna De Felice |
| collection | DOAJ |
| description | Multiple sclerosis is an autoimmune neurodegenerative disease and one of the most significant challenges in modern neurology, impacting approximately 2.8 million people globally. As a multifactorial condition, susceptibility to MS can result from a combination of genetic and environmental factors. Current treatment strategies aim to prevent acute attacks, slow disease progression, and alleviate symptoms. Ocrelizumab, a monoclonal antibody targeting CD20, has demonstrated efficacy in clinical trials by reducing both disease activity and frequency of relapses.Given the recent approval of this treatment, we investigated whether Ocrelizumab alters the expression of key miRNAs and genes involved in neuroinflammation, such as let-7a-5p, miR-14a-5p, miR-21a-5p, miR-338-3p, IL-1, IL-6, NEAT1, NEFL, NESTIN, SLC16A10 and TNF-alpha, by comparing their expression in patients’ blood before and after one year of treatment with Ocrelizumab. Additionally, we explored potential inverse correlations and direct or indirect interactions among the genes and miRNAs that showed significant changes in expression. Lastly, we conducted a pathway analysis to understand the overall effects potentially exerted by the drug.Results revealed a significant decrease in the expression of TNF-alpha, SLC16A10, NEFL and IL-6, and an increase in let-7a-5p expression. There was an inverse correlation between let-7a-5p and the four genes, while the genes positively correlated with each other, suggesting let-7a-5p as a common modulator. These findings indicate that further investigation is needed to determine if the drug directly upregulates let-7a-5p, thereby downregulating the four genes, or if these expression changes are an indication of an overall reduction in inflammation. |
| format | Article |
| id | doaj-art-0bcfab3b038b4b9b910cd9c9b835e13a |
| institution | Matheson Library |
| issn | 2468-0540 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Non-coding RNA Research |
| spelling | doaj-art-0bcfab3b038b4b9b910cd9c9b835e13a2025-08-02T04:47:31ZengKeAi Communications Co., Ltd.Non-coding RNA Research2468-05402025-08-0113174183Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosisBruna De Felice0Elisabetta Signoriello1Concetta Montanino2Giuseppe Romano3Deborah Archetto4Elisabetta Maida5Martina Marciano6Simona Bonavita7Giacomo Lus8Federica Farinella9Cinzia Coppola10Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, Italy; Corresponding author.Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Via Vivaldi 43, 81100, Caserta, ItalyMultiple sclerosis is an autoimmune neurodegenerative disease and one of the most significant challenges in modern neurology, impacting approximately 2.8 million people globally. As a multifactorial condition, susceptibility to MS can result from a combination of genetic and environmental factors. Current treatment strategies aim to prevent acute attacks, slow disease progression, and alleviate symptoms. Ocrelizumab, a monoclonal antibody targeting CD20, has demonstrated efficacy in clinical trials by reducing both disease activity and frequency of relapses.Given the recent approval of this treatment, we investigated whether Ocrelizumab alters the expression of key miRNAs and genes involved in neuroinflammation, such as let-7a-5p, miR-14a-5p, miR-21a-5p, miR-338-3p, IL-1, IL-6, NEAT1, NEFL, NESTIN, SLC16A10 and TNF-alpha, by comparing their expression in patients’ blood before and after one year of treatment with Ocrelizumab. Additionally, we explored potential inverse correlations and direct or indirect interactions among the genes and miRNAs that showed significant changes in expression. Lastly, we conducted a pathway analysis to understand the overall effects potentially exerted by the drug.Results revealed a significant decrease in the expression of TNF-alpha, SLC16A10, NEFL and IL-6, and an increase in let-7a-5p expression. There was an inverse correlation between let-7a-5p and the four genes, while the genes positively correlated with each other, suggesting let-7a-5p as a common modulator. These findings indicate that further investigation is needed to determine if the drug directly upregulates let-7a-5p, thereby downregulating the four genes, or if these expression changes are an indication of an overall reduction in inflammation.http://www.sciencedirect.com/science/article/pii/S2468054025000575Multiple sclerosisOcrelizumabmiRNAsInteraction networkPathway analysisInflammation |
| spellingShingle | Bruna De Felice Elisabetta Signoriello Concetta Montanino Giuseppe Romano Deborah Archetto Elisabetta Maida Martina Marciano Simona Bonavita Giacomo Lus Federica Farinella Cinzia Coppola Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis Non-coding RNA Research Multiple sclerosis Ocrelizumab miRNAs Interaction network Pathway analysis Inflammation |
| title | Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis |
| title_full | Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis |
| title_fullStr | Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis |
| title_full_unstemmed | Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis |
| title_short | Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis |
| title_sort | role of ocrelizumab in modulating gene and microrna expression in multiple sclerosis |
| topic | Multiple sclerosis Ocrelizumab miRNAs Interaction network Pathway analysis Inflammation |
| url | http://www.sciencedirect.com/science/article/pii/S2468054025000575 |
| work_keys_str_mv | AT brunadefelice roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT elisabettasignoriello roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT concettamontanino roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT giusepperomano roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT deboraharchetto roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT elisabettamaida roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT martinamarciano roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT simonabonavita roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT giacomolus roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT federicafarinella roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis AT cinziacoppola roleofocrelizumabinmodulatinggeneandmicrornaexpressioninmultiplesclerosis |